| UC Davis & UCSD & UCI & UCSF & City of Hope |
|
Pact Pharma & CIRM |
Solid tumors |
A Phase 1a/1b, Open Label First In Human Study Of The Safety, Tolerability And Feasibility Of Gene Edited Autologous NeoTCR T Cells (NeoTCR-P1) Administered As A Single Agent Or In Combination With Anti PD-1 To Patients With Locally Advanced Or Metastatic |
No longer active |
|
| UC Davis |
|
UC Davis/CIRM |
Spina bifida |
Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele |
Recruiting |
|
| UC Davis |
|
Orca Biosystems, Inc. |
Hematologic Malignancies |
A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood, With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
Recruiting |
|
| UC Davis |
|
Atara Bio. |
EBV-PTLD |
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) |
No longer active |
|
| UC Davis |
|
Kite Pharma |
Advanced Cancer |
A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers |
No longer active |
|
| UC Davis |
|
Pluristem Ltd. |
Muscle Injury - hip fracture |
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty |
Recruiting |
|
| UC Davis |
|
Medeor Therapuetics |
Kidney Transplant |
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants |
No longer active |
|
| UC Davis |
|
UC Davis |
B-Cell Leukemia |
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies |
Active, not recruiting |
|
| UC Davis |
|
UC Davis |
Cancer - Lymphoma (HIV-Related) |
Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
Recruiting |
|
| UC Davis |
|
Nohla Therapeutics |
Cancer – Leukemia |
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML |
No longer active |
|
| UC Davis |
|
Capricor Therapeutics |
Muscle - Duchenne Muscular Dystrophy |
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) |
No longer active |
|
| UC Davis |
|
UC Davis |
Cancer - Tongue Dysphagia |
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia |
Recruiting |
|
| UC Davis |
|
UC Davis |
Eye - Retinopathy |
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy |
Recruiting |
|
| UCI |
|
Cartesian Therapeutics |
MYASTHENIA GRAVIS (MG) |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Recruiting |
|
| UCI & UC Davis |
|
Celularity, Inc. |
Hospitalized COVID-19 patients |
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 |
Active, not recruiting |
|
| UCI |
|
Pluristem Ltd. |
Intubated COVID-19 patients |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19 |
No longer active |
|
| UCI |
|
Brain Neurotherapy Bio |
Parkinson's |
Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease |
Active, not recruiting |
|
| UCI |
|
ReNeuron Limited |
Stroke |
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III) |
No longer active |
|
| UCI |
|
Pluristem Ltd. |
Critical Limb Ischemia (CLI) |
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor |
No longer active |
|
| UCI & UC Davis |
|
Humacyte |
Kidney failure |
A Phase 3 Study to Compare the Efficacy and Safety of Humacyte’s Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease |
Active, not recruiting |
|
| UCI |
|
Stratetech |
Burn wounds |
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements |
No longer active |
|
| UCI & UCSD & UC Davis |
|
Aivita Biomedical |
Cancer - Brain |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
Active, not recruiting |
|
| UCI |
|
Longeveron |
Aging frailty |
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty |
Active, not recruiting |
|
| UCI |
|
BrainStorm Cell Therapeutics |
Amyotrophic Lateral Sclerosis (ALS) |
A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS |
No longer active |
|
| UCI |
|
jCyte |
Eye - Retinitis Pigmentosa (RP) |
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa |
No longer active |
|
| UCI |
|
SanBio |
Stroke |
Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke |
No longer active |
|
| UCI |
|
ImmunoCellular Therapeutics |
Cancer - Brain |
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma |
No longer active |
|
| UCI & UC Davis |
|
Humacyte |
Kidney Failure |
An Assessment of Humacyte’s Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
No longer active |
|
| UCLA |
Scott Nowicki, MD, PhD
|
UCLA |
Cancer - Solid Tumors |
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies |
No longer active |
|
| UCLA |
|
UCLA |
Cancer - Lung |
A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
Active, not recruiting |
|
| UCLA |
|
UCLA |
Cancer |
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) |
No longer active |
|
| UCLA |
|
Calimmune |
HIV/AIDS |
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection |
No longer active |
|
| UCLA |
|
UCLA |
X-linked Chronic Granulomatous Disease |
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease |
Active, not recruiting |
|
| UCLA |
|
UCLA |
Sickle Cell Disease |
Stem Cell Gene Therapy for Sickle Cell Disease |
Recruiting |
|
| UCLA |
|
UCLA |
Severe Combined Immunodeficiency (SCID) |
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) |
Active, not recruiting |
|
| UCLA |
|
Orchard Therapeutics |
Severe Combined Immunodeficiency (SCID) |
Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency |
Active, not recruiting |
|
| UCLA & UCI |
|
SanBio |
Brain Injury |
A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) |
No longer active |
|
| UCSD |
|
UCSD & CIRM |
Cystinosis |
Stem cell gene therapy for cystinosis |
Recruiting |
|
| UCSD |
|
Tigenix |
Crohn's Disease |
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) |
Active, not recruiting |
|
| UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
Long term follow-up study for patients administered CLBR001 , a CAR-T cell |
No longer active |
|
| UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies |
No longer active |
|
| UCSD |
|
Fate Therapeutics |
Solid tumors |
FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors |
No longer active |
|
| UCSD |
|
UCSD/Oncternal |
chronic lymphocytic leukemia |
Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax |
Active, not recruiting |
|
| UCSD |
|
Aivita |
Ovarian and Fallopian Tube Carcinoma |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas |
Active, not recruiting |
|
| UCSD |
|
Discgenics |
Degenerative Disc Disease |
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration |
No longer active |
|
| UCSD |
|
UCSD |
Cancer - Breast |
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
Active, not recruiting |
|
| UCSD |
|
Persimmune, Inc. |
Cancer - Blood |
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) |
No longer active |
|
| UCSD & City of Hope |
|
UCSD |
Cancer - Leukemia |
A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
Active, not recruiting |
|
| UCSD |
|
Persimmune, Inc. |
Cancer - Blood |
Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens |
No longer active |
|
| UCSD |
|
Asterias Biotherapeutics |
Spinal Cord Injury |
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury |
No longer active |
|
